Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
19.39
-0.51 (-2.56%)
Mar 31, 2025, 9:49 AM EDT - Market open
Genmab Revenue
In the year 2024, Genmab had annual revenue of 21.53B DKK with 30.67% growth. Genmab had revenue of 6.44B in the quarter ending December 31, 2024, with 35.34% growth.
Revenue (ttm)
21.53B DKK
Revenue Growth
+30.67%
P/S Ratio
4.21
Revenue / Employee
8,038,088 DKK
Employees
2,678
Market Cap
12.58B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GMAB News
- 1 hour ago - Transactions in connection with share buy-back program - GlobeNewsWire
- 3 days ago - Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer - Benzinga
- 4 days ago - TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy - GlobeNewsWire
- 5 days ago - Genmab Announces Initiation of Share Buy-Back Program - GlobeNewsWire
- 9 days ago - Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - GlobeNewsWire
- 13 days ago - Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer - Business Wire
- 16 days ago - Genmab: GEN3014's Demise And Implications For The HexaBody Platform - Seeking Alpha
- 18 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire